Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 6/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743744 | 0.74 | SIGMAR1 (0.36) | KDM1ASCN1ASCN2ASCN3AIDO1 | |
| SCHEMBL3616103 | 0.68 | CYP19A1 (0.45) | CYP19A1KDM1A | |
| SCHEMBL1129324 | 0.67 | KDM1A (0.46) | CYP19A1KDM1A | |
| SCHEMBL27185199 | 0.65 | KDM1A (0.53) | KDM1ASCN1ASCN2ASCN3ASIGMAR1 | |
| SCHEMBL12060813 | 0.62 | CYP19A1 (0.37) | CYP19A1 | |
| SCHEMBL1129017 | 0.62 | SIGMAR1 (0.39) | CYP19A1SIGMAR1 | |
| SCHEMBL779589 | 0.61 | KDM1A (0.38) | KDM1ASIGMAR1 | |
| SCHEMBL1129028 | 0.60 | SIGMAR1 (0.43) | KDM1ASIGMAR1 | |
| SCHEMBL666915 | 0.58 | HTR2A (0.55) | KDM1ASIGMAR1 | |
| SCHEMBL11722413 | 0.58 | KDM1A (0.40) | KDM1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885KDM1A 1046/4885SCN1A 3499/4885 |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885KDM1A 1046/4885SCN1A 3499/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885KDM1A 1046/4885SCN1A 3499/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885KDM1A 1046/4885SCN1A 3499/4885 |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | CYP19A1 67/4885KDM1A 3415/4885SCN1A 448/4885 |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885KDM1A 1046/4885SCN1A 3499/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885KDM1A 1046/4885SCN1A 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.